Dr Marc Raab speaks to ecancer about the MajesTEC-5 study presented at ASH 2024. The study explores the impact of adding teclistamab, a first-in-class B-cell maturation antigen (BCMA) bispecific IgG4 antibody to standard of care in newly diagnosed transplant-eligible multuple myeloma patients.

Patients were treated with either teclistamab with daratumumab, lenalidomide and dexamethasone or teclistamab with daratumumab, lenalidomide, dexamethasone and bortezomib. 

Dr Raab reports that all patients achieved complete remission with all tested patients showing MRD negativity after three cycles, indicating a promising new standard of care.